The WHO has given a green light to widespread use of GlaxoSmithKline's malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The RTS,S/AS01 vaccine ...

together with GSK and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI.

Being the only product on the market, GSK’s vaccine has dominated the shingles ... helping develop vaccines such as ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

Vaccines are a vital new tool to stop children in poor countries falling sick and dying of malaria. Though not perfect, they ...

33; www.gsk.com). The vaccine production process itself can ... initiatives that aim to reduce the burden of diseases such as malaria and tuberculosis, and new ways to tackle anti-microbial ...

For example, the malaria vaccine is a result of 30 years of research and development by the British pharmaceutical company, GlaxoSmithKline (GSK) through a partnership with the global public ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Both the Sanaria and the GlaxoSmithKline projects receive support from the PATH Malaria Vaccine Initiative, a program at the nonprofit PATH established through an initial grant from the Bill ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...